Tumor metastasis is the major cause of death among cancer patients, with 490% of cancer-related death attributable to the spreading of metastatic cells to secondary organs. Store-operated Ca 2+ entry (SOCE) is the predominant Ca 2+ entry mechanism in most cancer cells, and stromal interaction molecule 1 (STIM1) is the endoplasmic reticulum (ER) Ca 2+ sensor for store-operated channels. Here we reported that the STIM1 was overexpressed in colorectal cancer (CRC) patients. STIM1 overexpression in CRC was significantly associated with tumor size, depth of invasion, lymph node metastasis status and serum levels of carcinoembryonic antigen. Furthermore, ectopic expression of STIM1 promoted CRC cell motility, while depletion of STIM1 with short hairpin RNA inhibited CRC cell migration. Our data further suggested that STIM1 promoted CRC cell migration through increasing the expression of cyclooxygenase-2 (COX-2) and production of prostaglandin E2 (PGE2). Importantly, ectopically expressed COX-2 or exogenous PGE2 were able to rescue migration defect in STIM1 knockdown CRC cells, and inhibition of COX-2 with ibuprofen and indomethacin abrogated STIM1-mediated CRC cell motility. In short, our data provided clinicopathological significance for STIM1 and SOCE in CRC progression, and implicated a role for COX-2 in STIM1-mediated CRC metastasis. Our studies also suggested a new approach to inhibit STIM1-mediated metastasis with COX-2 inhibitors.
INTRODUCTION
Ca 2+ is a ubiquitous and versatile secondary messenger, regulating a variety of physiological and pathological processes such as immune response, exocytosis, cell migration, axon guidance and tumor dissemination. [1] [2] [3] [4] [5] In non-excitable cells, including majority of tumor cells, the store-operated Ca 2+ channels (SOC) are the major Ca 2+ entry mechanism. 3 Recently the stromal interaction molecule 1 (STIM1) and Orai1 were identified to be critical protein components in store-operated Ca 2+ entry (SOCE) pathways. 6, 7 STIM1 and the closely related STIM2 are endoplasmic reticulum (ER) Ca 2+ sensors activated by the decrease in ER Ca 2+ concentration. 8 Orai1 is the major channel pore-forming unit for SOC in plasma membrane. Upon Ca 2+ release from the ER, STIMs aggregate and translocate to the ER-plasma membrane to activate Orai1. 9 We previously reported that Ca 2+ influx is important for tumor cell migration, and both Orai1 and STIM1 are essential for breast tumor cell migration, invasion and metastasis. 2, 4 STIM1 and Orai1 regulate focal adhesion turnover in migrating cells through Ras and Rac. 2 Since our initial report of the roles of STIM1 and Orai1 in breast cancer metastasis, these two proteins have been implicated in the migration, invasion, proliferation and metastasis of cervical cancer, non-small cell lung cancer, breast cancer and melanoma. [10] [11] [12] [13] The regulation of the migration of non-cancer cells by STIM1 and Orai1 has also been reported. 14, 15 Storeindependent activation of Orai1 by SPCA2 also contributes to breast cancer tumorigenesis through activation of MAPK. 16 There is now a growing body of literature supporting crucial roles of STIM1 and Orai1 in the invasion and metastasis of various cancers. 3 However, clinicopathological evidence supporting the roles of SOC in cancer progression is lacking, and the molecular mechanism by which SOCE promotes cancer cell motility, invasion and metastasis is not clear.
Colorectal cancer (CRC) is the fourth most common cancer in men and the third in women, with approximately one million new cases in 2002 (9.4% of the world total), and 529 000 deaths due to CRC are reported around the world annually. 17 Tumor metastasis is responsible for virtually all cancer-related death in CRC patients; however, the molecular mechanisms underlying CRC cancer dissemination are not fully understood. In this study we examined the clinicopathological roles of STIM1 in CRC progression and metastasis. Our data demonstrated that STIM1 was overexpressed in CRC specimens, and the expression levels of STIM1 positively correlated with tumor size, stage, depth of invasion, lymph node metastasis and the serum levels of carcinoembryonic antigen (CEA) in CRC patients. Ectopic expression of STIM1 in CRC cells induced the expression of pro-inflammatory and pro-metastasis enzyme cyclooxygenase-2 (COX-2). Importantly, inhibition of COX-2 with two non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen and indomethacin, abrogated STIM1-induced CRC cell migration. Our finding suggested that STIM1 overexpression in CRC patients promote invasion and metastasis through upregulating COX-2 expression levels, and NSAIDs might be used to block STIM1-mediated CRC progression.
RESULTS

STIM1 overexpression correlates with CRC tumor invasion, tumor size and lymph node metastasis
To investigate the clinicopathological role of STIM1 in CRC progression, we employed immunohistochemistry staining using an anti-STIM1 antibody to examine the expression levels of STIM1 protein in CRC tissue specimens. The STIM1 antibody successfully stained paraffin-embedded control DLD-1 CRC cells, but not DLD-1 cells expressing STIM1 short hairpin RNA (shRNA), confirming the specificity of the antibody (Figure 1a ). To examine the role of STIM1 in CRC progression, we stained a tissue microarray consisting of 110 CRC samples for STIM1 expression. As shown in Figure 1b , STIM1 immunoreactivity appeared as diffuse cytoplasmic staining, consistent with the ER localization of STIM1. STIM1 was highly expressed in about two third (74 out of 110) of colorectal samples in the tissue microarray, as demonstrated by the strong STIM1 immunoreactivity in these samples (Figures 1b and c). Tumors with positive lymph node metastasis and advanced stages also had higher levels of STIM1 expression (Figures 1c-e ). When the tumors were stratified into two groups based on STIM1 staining intensity, 'STIM1 high' group had significantly higher and tumor stage (c and e). P-value was calculated by two-tailed Fisher's exact test. OR and CI in c refer to odds ratio and confidence interval, respectively.
incidence of advanced stage tumor (52.7%, 39 out of a total of 74) and tumor with lymph node and/or distant metastasis (51.4%, 38 out of a total of 74) when compared with the 'STIM1 low' group (30.6 and 30.6%, 11 and 11 out of a total of 36, respectively) ( Figure 1c ), suggesting that STIM1 overexpression might contribute to CRC progression and metastasis.
To further investigate the role of STIM1 in CRC progression and metastasis, we examined the expression levels of STIM1 in a cohort of 38 CRC patients treated at the Kaohsiung Medical University Hospital with a different approach (Table 1) . Tumor tissues and paired adjacent normal tissues were collected from these patients according to an Institutional review boardapproved protocol. Total messenger RNA (mRNA) from these samples was extracted and STIM1 expression levels in these samples were evaluated using quantitative real-time PCR. As shown in Figure 2a , STIM1 expression levels in tumors were elevated in 19 out of the 38 CRC patients when compared with the paired adjacent normal tissue. We further used enzyme-linked immunosorbent assay (ELISA) to compare the protein expression levels of STIM1 in another 20 paired CRC specimens and adjacent normal tissue. STIM1 protein levels increased in 90% of CRC samples (18 out of 20), suggesting the hyperactivation of storeoperated calcium entry in CRC patients ( Supplementary Figure 1) . To investigate the clinical significance of STIM1 overexpression in CRC progression, we studied the relationship between STIM1 expression levels and the clinicopathological data from CRC patients. As shown in Table 1 , there were statistically significant correlation between STIM1 expression levels and the tumor size, depth of tumor invasion, lymph node metastasis status and UICC stages of CRC. The percentage of CRC samples with high STIM1 expression levels more than doubled in tumors ⩾ 5 cm (68.6%) when compared with the o5 cm group (31.6%; Table 1 , Figure 2b ). Intriguingly, all the 19 CRC cases with STIM1 overexpression had deep invasion (T3 and T4): either invasion completely through the muscularis propria into the serosa layer (T3) or in some cases had grown through the colon wall and invaded other organs or tissues (T4); no STIM1 overexpression was detected in the five CRC cases with shallower invasion (T1 and T2; Table 1 , Figure 2c ). Consistent with our immunohistochemistry staining results (Figure 1 ), 65.2% of lymph node metastasis positive CRC patients also had high STIM1 levels; in contrast, STIM1 overexpression was only detected in 26.7% of lymph node negative patients. (Table 1, Figure 2d ). Patients with high levels of STIM1 expression were about twice as likely to develop metastasis (15 out of a total of 19 cases) as patients with low STIM1 levels (8 out of 19; Table 1 , Figure 2d ).
When analyzed with multivariate analysis, the correlation between STIM1 expression levels and lymph node metastasis and tumor stages showed borderline significance (P = 0.0527 and 0.08, respectively; Supplementary Table 1 ). Collectively, our data indicated that STIM1 might promote CRC progression by mediating tumor invasion and metastasis.
Elevated levels of pre-operative serum CEA in CRC patients with STIM1 overexpression The levels of serum pre-operative CEA in CRC patients is a critical prognosis marker, with significantly higher CEA levels in patients with advanced CRC and poorer disease-free survival. 18 To further understand the pathological significance of STIM1 in CRC progression, we determined the serum CEA levels in the Kaoshiung cohort (Figure 2e ). Peripheral blood samples from the CRC patients were collected o 1 week prior to the operation, and the levels CEA in these samples were determined using an ELISA assay. The pre-operative CEA in the STIM1 high group (37.7 ± 16.8 ng/ml) is about five times as high as the CEA in STIM1 low group (7.7 ± 2.8 ng/ml). The STIM1 expression ratio (cancer vs normal) significantly correlated with pre-operative serum CEA in the cohort of 38 patients (Pearson correlation coefficient r = 0.35, Po 0.02) (Figure 2e ). The significant correlation between STIM1 expression ratio and pre-operative CEA suggested that patients with elevated STIM1 expression in tumor specimens might have poorer prognosis. STIM1 is critical for CRC cell migration A critical signature of metastatic cancer cells is elevated mobility and invasiveness, which facilitate malignant cells to overcome multiple barriers during dissemination. To understand the mechanisms by which STIM1 promotes CRC progression and metastasis, we examined the effects of ectopic STIM1 overexpression on CRC cell migration. Ectopic expression of STIM1 in DLD-1 CRC cells promoted thapsigargin (TG) induced SOCE (Figures 3a and b ). Next, the migration of DLD-1 cells expressing Abbreviations: MD, moderately well differentiated; PD, poorly differentiated; STIM1, stromal interaction molecule 1; UICC, International Union Against Cancer; WD, well differentiated. a A P-valueo0.05 was considered statistically significant. b Adjusted the effects of age, sex and location (colon and rectum).
control vector of ectopic STIM1 was examined using a Boyden chamber assay (Becton Dickenson, Franklin Lakes, NJ, USA). As shown in Figure 3c , activation of SOCE through ectopic expression of STIM1 promoted the migration of DLD-1 cells by about twofold.
To determine whether STIM1 was required for CRC cell migration, we employed three shRNAs to knockdown STIM1 in three colon cancer cell lines (DLD-1, HCT-116 and SW480), which decreased STIM1 protein levels by 50-90% ( Figure 3d ) and inhibited TGinduced SOCE (Figures 3e and f). Depletion of STIM1 protein with shRNA or inhibition of SOCE with two pharmaceutical inhibitors, 2-APB and SKF96365, robustly inhibited the migration of all three CRC cells ( Figure 3g ). In contrast, depletion of STIM1 with shRNA didn't have noticeable effect on the proliferation of CRC cells ( Supplementary Figure 2 ). Next, we determined the role of STIM1 in epidermal growth factor (EGF)-induced cell migration using a wound-healing cell migration assay. In these assays, CRC cells were grown to a confluent monolayer, and a 'wound' was made by scratching the CRC cell monolayer. 4, 19 After 48 h in the presence of 25 ng/ml EGF, CRC cells migrated into the gap to fill the 'wound'. As shown in Figure 3h , STIM1 knockdown remarkably inhibited EGF-mediated wound-closing in SW480 cells. Taken together, our data indicated that STIM1 overexpression might promote CRC metastasis by enhancing CRC cell motility and facilitating dissemination.
STIM1 promotes CRC cell migration by inducing COX-2 expression
There is increasing evidence that COX-2, a pro-inflammatory key enzyme in the synthesis of prostaglandins, plays important roles in CRC progression. 20 We recently reported that histamine and EGF induced the expression of COX-2 by activating NFAT and NFκB through store-operated Ca 2+ signaling. 21, 22 We hypothesized that hyperactive SOCE, as a result of STIM1 overexpression, would increase the levels of COX-2 in CRC. To examine this hypothesis we used quantitative reverse transcriptase-PCR to determine effects of ectopic STIM1 on COX-2 expression in DLD-1 cells. As shown in expression of STIM1 in HT-29 and Caco-2 cells not only dramatically increased the basal levels of COX-2 mRNA, but also significantly enhanced EGF-induced increase in COX-2 expression. The STIM1-mediated overexpression of COX-2 in DLD-1, HT-29 and Caco-2 cells were further confirmed with quantitative real-time PCR and western blot (Figures 4c and d) . The expression of COX-1 in HT-29 cells was not affected by either STIM1 or EGF treatment (Figure 4c ).
To examine the roles of STIM1-mediated COX-2 overexpression in CRC cell migration, we ectopically expressed COX-2 in control and STIM1 knockdown DLD-1 cells. We observed increased cell migration in DLD-1 cells after ectopic expression of COX-2 ( Figure 4e ). Importantly, COX-2 overexpression was able to rescue the inhibition of DLD-1 cell migration by STIM1 knockdown. Prostaglandin E2 (PGE2) levels in DLD-1 and HT-29 conditioned medium increased by two to threefold after STIM1 overexpression ( Figure 4f ), suggesting that STIM1-mediated COX-2 overexpression would lead to increased production of prostaglandins by CRC cells. Moreover, exogenously supplemented PGE2 was able to stimulate cell migration and rescued STIM1 knockdown effects in DLD-1 and HCT-116 cells (Figure 4g ). We further used ibuprofen and indomethecin, two commonly used non-steroid anti-inflammatory drugs, to inhibit COX-2 activity in CRC cells. As shown in Figure 4h , treatment with ibuprofen and indomethecin inhibited the migration of DLD-1 cells and HCT-116 cells by about 70%. Strikingly, the ectopic STIM1-promoted DLD-1 cell migration was almost completely abolished in the presence of ibuprofen and indomethecin. Taken together, our data suggested that elevated levels of STIM1-induced COX-2 expression and prostaglandin synthesis, which was critical for CRC cell motility.
DISCUSSION
Despite significant progress in our understanding of cancer dissemination in the last decade, the roles of Ca 2+ in cancer metastasis remained poorly understood. 3 Recent studies from our group and others have suggested the importance of SOCE in the progression of various cancers. 2, 3, [11] [12] [13] 21 Our previous studies indicated that SOCE channels could be potential cancer therapeutic targets for breast cancer. 2 Indeed, several groups already showed that blockage of SOCE inhibited the migration, invasion and proliferation of cancer cells. 10, 11, 23, 24 It is not clear, however, whether SOCE is dysregulated in tumors, or how dysregulated SOCE contribute to tumor progression. Here we provide evidence that STIM1, an essential component in SOCE, is overexpressed in CRC and elevated levels of STIM1 promotes CRC progression and CRC cell migration. STIM1 overexpression in CRC patients significantly correlates with CRC invasion, tumor size, lymph node metastasis and the serum levels of CEA. Although the prognositic value of pre-operative CEA levels in CRC patient is still a matter of debate, there is convincing evidence supporting the correlation between CEA values and CRC metastasis at the time of presentation. Orai1 expression was also upregulated in 480% of CRC surgical samples, further supporting the hyperactivation of SOCE pathway during CRC progression. In contrast, the expression of TRPV6 in CRC patient specimens had no correlation with clinicopathological parameters ( Supplementary Figure 3) . Our data suggested that hyperactive SOCE promoted CRC progression and metastasis.
STIM2 is a STIM1 homolog that involves in stabilizing cytosolic and ER Ca 2+ levels through feedback mechanisms. 8 It has been recently reported that STIM2 was overexpressed in CRC patients and yet STIM2 overexpression puzzlingly suppressed CRC tumor formation. 25 It was also previously suggested that STIM1/STIM2 expression ratio served as a potential prognostic marker for breast cancer. 26 However, we found no significant correlation between STIM2 expression levels and CRC progression ( Supplementary  Figure 3) . The role of STIM2 in cancer progression is an understudied area and future investigation is warranted.
COX-2 is overexpressed in about 90% of CRCs and 50% of adenomas, and is associated with poor prognosis among CRC patients. 20 We recently reported that SOCE was essential for EGF and histamine-induced COX-2 expression. 21, 22 In the current study, we further demonstrated that activation of SOCE through ectopic STIM1 dramatically increased both basal COX-2 and EGF-induced COX-2 expression in multiple CRC cell lines, including DLD-1, a CRC cell line with very low basal COX-2 levels.
Importantly, inhibition of COX-2 with ibuprofen and indomethacin, two commonly used NSAIDs, not only inhibited CRC cell migration, but also abolished elevated mobility in STIM1 overexpressing CRC cells. NSAIDs are drugs most commonly to relieve pain, fever and inflammation. Recent clinical studies provided interesting data supporting the roles of NSAIDs and other antiinflammatory drugs in the prevention of CRC. 20 Our data suggested that NSAIDs and selective COX-2 inhibitors might also be beneficial to block CRC metastasis, especially in patients with hyperactive SOCE activity. It was recently reported that the inhibition of SOCE by curcumin might contribute to its anti-inflammatory effect. 27 It remained to be determined whether curcumin might be useful in inhibiting STIM1-mediated COX-2 overexpression.
Interestingly, NSAIDs also inhibited the migration of DLD-1, a CRC cell line with very low COX-2 basal levels. The NSAID inhibitory effects could be in part attributed to the inhibition of COX-1, which has a housekeeping role in prostaglandin production. It is also possible the NSAID effects is partially due to their off-target inhibition of SOCE, as recently reported by Munoz et al. 28 Nonetheless, ectopic COX-2 and PGE2 were sufficient to rescue the STIM1 knockdown effect, suggesting that STIM1-mediated CRC cell migration was at least partially due to its regulation of COX-2 expression and prostaglandin synthesis. The role of COX-2, however, may not be limited to CRC cell migration. It is worth noting that although STIM1 knockdown had no effect on CRC cell proliferation in vitro, STIM1 overexpressing tumors tend to be bigger. It would be intriguing to determine whether STIM1 regulates CRC growth through COX-2 and prostaglandin-mediated angiogenesis and inflammatory cell recruitment.
It is intriguing to note that STIM1 was originally reported to be a putative tumor suppressor gene candidate based on its localization on human chromosome region 11p15.5. While the loss of 11p13-11p15.5 has been associated with several malignancies; evidence supporting the tumor suppressor role of STIM1 is scarce. It would be interesting to determine whether STIM1 may alternatively be a tumor suppressor in a different context. It is also worth noting that the proto-oncogene HRAS is also localized to 11p15.5.
Recent reports from other groups and ours suggested that the SOCE pathway is frequently dysregulated to promote cancer cell migration, invasion, metastasis and tumor growth in various cancers. 2, [10] [11] [12] [13] [21] [22] [23] 26, [29] [30] [31] The association of STIM1 with CRC lymph node metastasis, pre-operative CEA levels and cell migration suggested that STIM1 dysregulation in CRC may promote CRC distant metastasis and correction of dysregulated SOCE may improve disease-free and overall survival in CRC patients. With that said, cancer metastasis is a complicated, multistep event and cell migration is only part of the metastatic process. It would be important to determine the association between STIM1 and CRC prognosis in a large cohort of CRC patients, and to establish the causal role of STIM1 in CRC metastasis using xenograft or genetically engineered CRC mouse models in future research endeavors.
MATERIALS AND METHODS
Immunohistochemistry staining
CRC tissue microarray with TNM staging information, tumor grade and tumor stage was purchased from Biomax (Rockville, MD, USA). Tissue microarray slides were baked in a 60°C oven for 60 min, deparafinized and hydrated to dH2O. Epitope was retrieved by incubating with 0.21% citrate buffer (pH 6) in a 99°C water bath for 30 min. After epitope retrieval, slides were washed in running water for 2-5 min, incubated with 3% H 2 O 2 for 5 min and washed with dH 2 O and phosphate-buffered saline (PBS). After incubating with normal serum (1:20, diluted in 2% BSA/PBS) for 10 min at room temperature in a humidity chamber, slides were incubated with 150 μl monoclonal anti-STIM1 antibody (1:300; Thermo Scientific, Waltham, MA, USA) at 4°C in a humidity chamber overnight. Slides will then be washed with PBS (three times, 10 min each) and incubated with peroxidase-conjugated anti-mouse secondary antibody (1:500) at room temperature for 60 min. After three washes with PBS (10 min each), slides were transferred to a bath of diaminobenzidine (DAB) for 5-15 min, washed in running water for 1 min, and then counter stained using Harris modified hemotoxylin (Fisher, Waltham, MA, USA). Slides were then dehydrated and mounted. The results of STIM1 immunohistochemical staining was estimated by two investigators without knowledge of patient's clinical information. The staining intensity of STIM1 was graded on a scale from 0 to 3 (0 for no staining, 1 for weak immunoreactivity, 2 for moderate immunoreactivity and 3 for strong immunoreactivity). The percentage of immunoreactivity was scored on a scale from 0 to 3 (0 for no positive cells, 1 for o 25% of cells positive, 2 for 25-50% of cells positive and 3 for 450% of cells positive). The staining intensity score and the percentage of immunoreactivity score were then multiplied to obtain a composite score (CS). Depending on the CS, STIM1 expression was classified as high expression (CS 46) and low expression (CS ⩽ 6).
Cell migration assay
Transwell cell migration assay was carried out as previously described. 2, 32, 33 Cells (1 × 10 5 ) suspended in starvation medium were added to the upper chamber of an insert (6.5 mm diameter, 8-μm pore size, Becton Dickenson), and the insert was placed in a 24-well dish containing starvation medium with or without 10% fetal bovine serum. Migration assays were carried out for 24 h. Cells were fixed with 3.7% formaldehyde, stained with crystal violet staining solution, and cells on the upper side of the insert were removed with a cotton swab. Three randomly selected fields (×10 objectives) on the lower side of the insert were photographed, and the migrated cells were counted. The migration was expressed as the average number of migrated cells in a field.
Wound healing assay
Cells were seeded in wells of Culture-Insert (Ibidi GmbH, Martinsried, Germany) for 24 h. The Culture-Inserts were removed to reveal the wound gap. The baseline and the wound closure after treatment were photographed using a digital camera attached to an inverted microscope (Nikon Eclipse Ti, Nikon, Tokyo, Japan) with a × 10 objective. 34 Patients and tissue specimens Enrolled in this study were 38 CRC patients (21 males and 17 females; mean age, 62.13 ± 15.75 years) treated at the Department of Surgery at Kaohsiung Medical University Hospital. These patients have American Joint Commission on Cancer/International Union Against Cancer (AJCC/UICC) stage I-III CRC. Patients with other malignant diseases in their medical history were excluded. Clinical stage and pathological features of primary tumors were defined according to criteria of the AJCC/UICC. 35 Written informed consent was obtained from all subjects and/or guardians for use of their tissue samples. Sample acquisition and subsequent use were approved by the institutional review board at the Kaohsiung Medical University Hospital. Complete medical history, physical examination and laboratory studies, including assessing serum CEA levels, were reviewed. Computed tomography or magnetic resonance imaging of abdomen, abdominal ultrasonography, and chest radiography, bone scans and colonoscopy were performed before surgical intervention. Tumor grading and normalcy of adjacent tissues were evaluated by pathologists. The relevant data were listed in Table 1 . Samples were further used for realtime PCR, ELISA and immunofluorescence analysis.
STIM1 ELISA
To determine whether STIM1 protein levels were elevated in CRC tissues, normal and tumor tissues were collected from a cohort of 20 patients (a different cohort from the 38 patients used in the quantitative PCR study) with colon cancer in KMUH. Frozen tissue was prepared to determine STIM1 expression by STIM1 ELISA kit (Cusabio Biotech, Wuhan, China). Briefly, 200 μg of tissue lysate was added into microplate and was incubated with pre-coated STIM1-specific antibody at 4°C overnight. The wells were then emptied and rinsed five times with washing buffer. Plate absorbance was measured at a wavelength of 450 nm.
Reverse transcription-PCR
Tumor tissues and paired adjacent normal tissues were collected from CRC patients. Total mRNA from these samples was extracted and STIM1 expression levels in these samples were evaluated using STIM1 primers: forward primer 5ʹ-AGA AAC ACA CTC TTT GGC ACC-3ʹ, reverse primer 5ʹ-AAT GCT GCT GTC ACC TCG-3ʹ; COX-2: forward primer 5ʹ-AGA CAG CGT AAA CTG CGC CTT T-3ʹ, reverse primer 5ʹ-CAG CAA TTT GCC TGG TGA ATG ATT C-3ʹ. Other primers used: STIM2: forward primer 5ʹ-TGA TCT TCA GTC CTG CAA GC-3ʹ, reverse primer 5ʹ-ACA AAG GTC ATG TGG GAT GC-3ʹ; Orai1: forward primer 5ʹ-TTC CTA GCT GAG GTG GTG CT-3ʹ, reverse primer 5ʹ-CGA TAA AGA TCA GGC CGA AG-3ʹ; COX-1: forward primer 5ʹ-CCT CAT GTT TGC CTT CTT TGC-3ʹ, reverse primer 5ʹ-GGC GGG TAC ATT TCT CCA TC-3ʹ and β-actin: forward primer 5ʹ-ATC TCC TTC TGC ATC CTG TCG GCA AT-3ʹ, reverse primer 5ʹ-CAT GGA GTC CTG GCA TCC ACG AAA C-3ʹ. The SYBR Green PCR master mix reagent (Applied Biosystems, Foster City, CA, USA) was used to amplify the complementary DNA and the products were detected by Applied Biosystems 7500.
Detection of serum CEA
A 3-ml sample of peripheral blood was obtained from enrolled patients less than 1 week prior to operation. Serum CEA levels were determined by means of an enzyme immunoassay test kit (DPC Diagnostic Product Co., Los Angeles, CA, USA) with the upper limit of 5 ng/ml defined as normal according to the manufacturers of the kits that were used.
Cell culture HT-29, DLD-1, HCT-116, Caco-2 and SW480 cells were bought from ATCC (Manassas, VA, USA). Cells were cultured (37°C, 5% CO 2 ) in F-12K Nutrient Mixture, Kaighn's Modification (GIBCO, Grand Island, NY, USA) with 10% fetal bovine serum, 10 mM HEPES (J.T.Baker), 10 mM TES (Sigma, St Louis, MO, USA), 50 μg/ml L-Ascorbic Acid (J.T.Baker, Center Valley, PA, USA), ITS supplement (Insulin/Transferrin/Sodium Selenite 0.01: 0.01 : 10 ng/ml, from Sigma), 10 μg/ml ECGS (Sigma) and 10% penicillin-streptomycin. For Ca 2+ imaging experiments, cells were prepared onto glass coverslips and used 24-48 h after plating.
STIM1 plasmid transfection
Cells were seeded in 6-cm plastic dishes 1 day before transfecting plasmid. STIM1 plasmids (Gifts from Professor Baba (RIKEN, Tokyo, Japan)) or control plasmids were transfected into cells by using lipofectamine 2000 (Invitrogen, Grand Island, NY, USA). Following transfection, the cells were cultured for 24 h and then prepared for EGF stimulation. For stable expression of STIM1, CRC cells were infected with retroviral vectors. Retroviral particles were prepared as previously described. 36 WST-1 cell proliferation assay Cells were harvested and then incubated with WST-1 reagent (Roche, Basel, Switzerland) at 37°C for 5 min. Absorbance was measured at 450 nm with background subtraction at 600 nm.
RNA interference
Stable knockdown of STIM1 was performed using pSUPER.Retro.puro vector (Oligoengine, Seattle, WA, USA) encoding small hairpin RNA. STIM1 sh1 and sh2 has been previously described. 2 STIM1 sh3 is targeting the following sequence: 5′-AGAAGGAGCTAGAATCTCAC-3′. A vector encoding non-targeting control shRNA was previously described. 37 Transient knockdown of STIM1 in CRC cancer cells were achieved through transfection of short-interfering RNA (siRNA) into cells using lipofectamine 2000 (Invitrogen, Inc.). The siRNA for STIM1 or control siRNA was purchased from Invitrogen, Inc. Cells were seeded in six-well plastic plates 1 day before applying siRNA.
Calcium imaging
The intracellular Ca 2+ responses were induced by application of TG (Sigma Aldrich, St Louis, MO, USA), according to methods previously described. 38 Before the experiments, cells were stained with 1 μM Fura2-AM (Molecular Probes, Life Technologies, Grand Island, NY, USA) at 37°C for 20 min and then washed with balanced salt solution buffer (5.4 mM KCl, 5.5 mM D-glucose, 1 mM MgSO 4 , 130 mM NaCl, 20 mM Hepes pH 7.4 and 2 mM CaCl 2 ). SOCE response were estimated based on the ratio of fluorescence intensities emitted upon excitation with consecutive 3-s pulses of 340/380 nm light at a resolution of 1376 × 1038 pixels using an Olympus Cell^R IX81 fluorescence microscope (Olympus, Tokyo, Japan) equipped with an MT 20 illumination system (Olympus) and UPLanApo 10 × objective lens (Olympus).
Western blotting
Total cell lysates (60 μg) were analyzed by SDS-polyacrylamide gel electrophoresis on a 12.5% gel. After electro-blotting to nitrocellulose membrane, membranes were blocked with non-fat dry milk for 2 h at room temperature. Membranes were washed with PBS with Tween 20 three times and then incubated with primary antibodies for 1 h at room temperature. Antibodies were obtained from the following sources: STIM1 and beta-actin from Cell Signaling (Danvers, MA, USA). Anti-STIM1 antibody was used at 1:3000 dilution. Anti-beta-actin was used at 1:8000 dilution. Then, membranes were washed with PBS with Tween 20 three times and incubated with 1:8000 dilution of peroxidase-linked anti-mouse IgG (Amersham Biosciences, Piscataway, NJ, USA) for 1 h at room temperature. After washing with PBS with Tween 20, the bands were detected by an ECL-plus western blotting detection system (Amersham Biosciences). Statistical analysis JMP 9.0 software for windows (SAS Institute, Cary, NC, USA) was used for the statistical analysis (univariate analysis, regression analysis and multivariate analysis). The difference between STIM1 expression level and clinical pathology features were performed by Χ 2 -test. The correction of age, gender and location were performed by multiple linear regression. In addition, the multivariate analysis was conducted to examine the associations between STIM1 expression level and multi factors. Regression analysis was performed to adjust the effect of age, gender and tumor location. Student's t-test was used, as indicated in the figure legends, when the data were normally distributed. A P-valueo 0.05 was considered statistically significant.
